Cataract surgery-induced dry eye may not be a direct consequence of surgery

Article

Dry eye following cataract surgery may not be a direct result of the surgery but rather the surgery triggers symptoms in eyes with pre-existing sub-optimal tear properties.

Dry eye following cataract surgery may not be a direct result of the surgery but rather the surgery triggers symptoms in eyes with pre-existing sub-optimal tear properties, according to Waheeda Illahi and colleagues from BMEC, City Hospital, Birmingham, UK.

A study was conducted to assess tear quantity, break-up time and central corneal thickness following cataract surgery. Tear quantity was measured using a phenol red thread, fluorescein break-up time (measured in seconds) was quantified by standard biomicroscopy and central corneal thickness was measured by ultrasonic pachymetry after topical anaesthesia. Measurements were taken from right eyes in bilateral cases and age and gender matched controls.

The results showed that mean phenol red thread was 16.9 mm in the study group and 16.5 mm in the controls. Mean break-up time was 4.9 seconds in the study group and 4.6 seconds in the controls. Mean central corneal thickness was 541.2 µm in the study group and 539.0 µm in the controls. Comparisons revealed no statistical differences between the two groups but there was a significant correlation between break-up time and phenol red thread in the study group (r=0.265, p=0.028).

Although dry eye symptoms are often reported after cataract surgery, this study suggests that surgery is not the direct cause but rather that the surgery triggers symptoms in eyes with pre-existing sub-optimal tear properties.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.